Oncology

Novo Nordisk
Biotech

Novo drops oncology ambitions, early-stage MASH prospects

The Danish pharma is winding down a range of early-stage programs for liver disease, oncology and stem cells.
James Waldron Nov 5, 2025 7:21am
GSK ESMO

GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets

Oct 29, 2025 6:29am
graphic of a larger shark chomping up a smaller one

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
antibody antibody-drug conjugate antibody drug conjugate ADC

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am
Graphic images of different entities adding money to a pile

Tubulis touts $361M series C as next-gen ADC data drop nears

Oct 15, 2025 5:01am
More News

Turbine looks to turbocharge AstraZeneca's ADC discovery

Oct 9, 2025 6:00am

3 scientists win Nobel Prize for discovery of regulatory T cells

Oct 6, 2025 7:03am

White House pledges $100M to AI pediatric cancer project

Oct 1, 2025 11:06am

Dana-Farber oncologist Anthony Letai tapped to direct NCI

Sep 30, 2025 5:50am